Recent Developments for Applied Therapeutics Investors
Investors in Applied Therapeutics, Inc. are facing a significant challenge after the unfortunate release of crucial information that impacted the company’s stock performance. The legal firm Levi & Korsinsky has reached out to these shareholders, indicating that a class action securities lawsuit is underway. This could provide an avenue for those who have suffered financial losses due to the company's recent turmoil.
Understanding the Class Action Lawsuit
The current class action lawsuit aims to represent those investors adversely affected by alleged securities fraud incidents related to Applied Therapeutics during a specified period. The timeline of concern stretches from the initial announcement of challenges with the New Drug Application for govorestat. The significance of this lawsuit lies in its potential to recover losses incurred by shareholders during this turbulent period.
Details of the Case
The complaint raises issues surrounding a Complete Response Letter (CRL) received from the FDA on November 27, which indicated that the agency could not approve the NDA as it stood, citing certain deficiencies. Following this announcement, the stock plunged dramatically. Investors watched in dismay as the stock plunged from $10.21 per share to a shocking $1.75 per share by December 2, marking a decline of over 80%.
Continued Stock Decline
Further compounding these losses, a disclosure followed revealing that Applied Therapeutics had received a warning letter from the FDA referring to clinical trial issues. This news exacerbated the stock's downward trajectory, with shares now trading at alarming lows, fueling investor fears and prompting them to seek justice through legal channels.
What Actions Can Affected Investors Take?
For those feeling the impact of these stock losses, the window for action is limited. Affected shareholders have until a set deadline to apply as lead plaintiffs in this class action lawsuit. It’s crucial to understand that filing as a lead plaintiff is not required to claim any recoveries that may come from the lawsuit.
No Financial Burden for Participants
There is good news for potential participants in this lawsuit. Individuals affected by the stock decline may be entitled to possible compensation without any upfront costs. This means they can join the class action without the fear of incurring out-of-pocket expenses, making legal recourse accessible to all affected investors.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has built a robust reputation over the last two decades, helping investors reclaim their losses and navigate through complex securities litigation. Their track record is impressive, having secured hundreds of millions in settlements for shareholders, demonstrating their capability and expertise to handle high-stakes cases.
Contact Information for Support
For those who wish to learn more about their rights or participate in this class-action suit, reaching out to Levi & Korsinsky is vital. Interested individuals can get in touch with Joseph E. Levi, Esq., either by phone or email. The firm encourages potential claimants to step forward and assert their rights in what could be a pivotal moment for many shareholders.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit aims to recover losses for investors affected by alleged securities fraud involving Applied Therapeutics.
How can I participate in the lawsuit?
Affected investors should contact Levi & Korsinsky before the stated deadline to learn about their options.
Is there any cost to participate?
No, participants can join the class action without incurring any fees.
What was the reason for the stock decline?
The decline resulted from FDA communications outlining issues with the company's drug application and subsequent warnings.
Why is Levi & Korsinsky a good choice for representation?
The firm has extensive expertise in securities litigation and a strong track record of winning significant settlements for investors.
